TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07491172: A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

Sponsor: CRISPR Therapeutics AG · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 90 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$1,354,560

Rescue Site Savings

+$903,040

Unlock Full NCT07491172 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07491172 Rescue Dossier →